TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$0.26 USD
+0.01 (2.41%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.26 0.00 (0.35%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Income Statements
Fiscal Year end for TransCode Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 19 | 6 | 1 | 0 |
Income After Depreciation & Amortization | -19 | -19 | -6 | -1 | 0 |
Non-Operating Income | 1 | 1 | -1 | -1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -19 | -18 | -7 | -2 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -19 | -18 | -7 | -2 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -19 | -18 | -7 | -2 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -19 | -6 | -1 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -19 | -19 | -6 | -1 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.18 | 0.02 | 0.01 | NA | NA |
Diluted EPS Before Non-Recurring Items | -103.61 | -1,080.00 | -648.00 | NA | NA |
Diluted Net EPS (GAAP) | -103.61 | -1,080.00 | -648.00 | NA | NA |
Fiscal Year end for TransCode Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.11 | 3.29 | 4.06 | 5.32 | 5.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.11 | -3.29 | -4.06 | -5.32 | -5.13 |
Non-Operating Income | -0.07 | -0.03 | 0.03 | 0.03 | 0.79 |
Interest Expense | 0.00 | 0.01 | 0.06 | 0.00 | 0.00 |
Pretax Income | -5.19 | -3.33 | -4.09 | -5.30 | -4.34 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.19 | -3.33 | -4.09 | -5.30 | -4.34 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.19 | -3.33 | -4.09 | -5.30 | -4.34 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 7.05 | 5.14 | NA | 0.08 | 0.03 |
Diluted EPS Before Non-Recurring Items | -0.74 | -0.65 | NA | -67.20 | -131.60 |
Diluted Net EPS (GAAP) | -0.74 | -0.65 | 359.19 | -67.20 | -131.60 |